Reuters logo
BRIEF-Molmed and TTY Biopharm enter into exclusive agreement to commercialise Zalmoxis in certain Asian territories
June 30, 2017 / 5:46 AM / 3 months ago

BRIEF-Molmed and TTY Biopharm enter into exclusive agreement to commercialise Zalmoxis in certain Asian territories

June 30 (Reuters) - MOLMED SPA:

* MOLMED AND TTY BIOPHARM ENTER INTO AN EXCLUSIVE AGREEMENT TO COMMERCIALISE ZALMOXIS® IN CERTAIN ASIAN TERRITORIES

* SAYS SIGNED AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WHICH DEFINES ALL TERMS AND CONDITIONS TO IMPORT, USE, MARKET, SELL AND/OR DISTRIBUTE ZALMOXIS FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES IN TAIWAN, HONG KONG, SINGAPORE, THAILAND, PHILIPPINES, VIETNAM AND MALAYSIA

* MOLMED WILL RECEIVE AN UPFRONT PAYMENT, POTENTIAL REGULATORY AND SALES MILESTONE PAYMENTS UP TO EURO 13.5 MILLION

* MOLMED WILL RECEIVE AS WELL ROYALTY PAYMENTS IN RANGE OF 10% TO 20% ON ANNUAL NET SALES GENERATED IN EACH COUNTRY COVERED BY THE AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below